The Asia-Pacific newborn screening market is driven by the support of government organizations promoting the initiatives in the treatment of fatal diseases in the region thereby helping the market to grow at the end of the forecast period of 2019-2027, the market is predicted to rise with a CAGR of 14.17%.
The South Korean newborn screening market contributed the highest CAGR value in 2018 owing to the increasing birth rate coupled with the newborn screening initiatives helping the market to grow in this region. As per the World Health Organization, around 0.48 million babies are born each year in South Korea which is likely to raise the adoption of newborn screening considering the complication that a newborn experiences.
Other significant markets in this region include India, China, Australia and the rest of Asia-Pacific.
Factors like raising awareness for pediatric congenital heart disease and an increase in the number of pregnant women with advanced maternal age are expected to drive the market growth in this region. Newborn screening reagents and assay kits are supposed to be the more popular product category in this market. However, a lack of skilled professionals to safely carry out these screenings is a major challenge faced by this market.
Market players like Sciex, Biotek Instruments Inc., Bio-Rad Laboratories Inc., Cardinal Health Inc., GE Healthcare Limited, Agilent Technologies Inc., Masimo Corporation, Natus Medical Incorporated, Medtronic PLC, Thermo Fisher Scientific Inc., Neogen Labs Pvt. Ltd., Perkinelmer Inc., Zentech S.A., Waters Corporation and Trivitron Healthcare are well-known in this region.